Treat the Supplier List as a Product Spec

On May 6 the FDA added neurosurgical patties, sponges, and strips to the Medical Device Shortages List, citing a Class 2 Medline Industries recall that began on March 13 after the company found higher-than-expected endotoxin levels on its branded neurosurgical pattie products, per the FDA letter to health care providers and MedTech Dive. The agency expects the disruption to extend through the end of 2026, and the HCP letter asks the field to diversify supply sources. The story is being read as a hospital-procurement problem. Inside it is the most expensive lesson hardware founders keep relearning every cycle. The supplier list inside a regulated hardware product is a product spec. It is part of the device. It belongs in the design history file as a design decision. The companies that finish in MedTech, diagnostics, defense, climate, and physical AI are the ones whose founders treated it that way from the prototype freeze, not the ones who left it as a procurement question for after the round closed.

If You Are Building a Company in This Environment

The default first-time hardware founder treats supplier qualification as a function downstream of design. The product team finishes the design, the regulatory team builds the design history file, the operations team qualifies the supplier list, and the assumption is that the design constraints flow downhill from prototype to procurement in that order. The trouble with the order is that the supplier’s validated process is the constraint, not the device’s nominal spec. A polymer that came from one extrusion line is not the same material that comes from a different extrusion line, even if the certificate of analysis says it is. A sterilization vendor running at one bioburden envelope produces a different product than one running at another envelope, even if both pass the agency’s threshold. The founders who finish hardware understand that the supplier list is the constraint that defines what the device actually is in practice, and they design around that constraint instead of trying to bolt it on after the fact.

Designing the supplier list as a product spec means three concrete things inside the operating cadence of the company. First, the bill of materials carries qualification status, process control data, and a second-source plan as first-class fields, with the same review discipline as a critical-to-quality dimension on the device drawing. Second, the design history file documents the rationale for every single-source decision, with a written cost of being wrong and a written trigger condition under which the company would invest in a redundant qualification. Third, the operating plan carries a redundant-qualification roadmap with its own line items in the capital plan, sized to the realistic likelihood that the company will face a supplier disruption inside the commercial window. The Medline recall did not happen because hospitals failed to forecast their neurosurgical caseload. It happened because the upstream qualification envelope drifted, and the companies that depended on the validated material had no redundant source ready to absorb the shock at category scale.

The same logic applies across diagnostics, IVD, combination products, defense hardware, climate hardware, and any other regulated or capital-intensive hardware category. The substrate changes from polymers and sterilants to semiconductors and rare-earth-bearing magnets to ion-exchange membranes and specialty cathode materials, but the geometry is the same. A founder who built the design history file as a list of single points of failure will pay for that decision somewhere in the commercial window. A founder who built it as a redundancy roadmap with explicit trigger conditions will pay the cost of the redundancy work upfront and avoid the cost of the disruption later. Founders Who Finish exists for exactly this kind of decision, where the right answer requires the founder to spend money in the prototype phase on a future state most of the team would rather not contemplate, and where the founder is the only person in the room whose job is to make that call early enough that the company can survive the failure mode that the rest of the world is currently watching play out on someone else’s product.

What the Neurosurgical Shortage Surfaces as a Case Study

The Medline neurosponge shortage is a useful case study because each operational consequence maps to a different design decision the company below the supplier should have made earlier. The Class 2 recall classification fixes the question of how serious the failure mode is. Higher-than-expected endotoxin levels create the possibility of febrile response and local inflammation, which are reversible adverse events but real ones, and which generate a regulatory record that follows the supplier and any downstream user of the supplier’s material. The shortage list classification fixes the question of whether substitute sources exist. The agency does not normally add a single-supplier recall to the shortages list, and the fact that this one landed there says the FDA assessed the rest of the supply base and found no near-term alternative, per Supply Chain Dive. The HCP letter’s explicit guidance to diversify supply sources fixes the question of where the agency expects the responsibility for redundancy to live. It is no longer a sourcing efficiency conversation. It is now a structural risk the agency has named publicly, and the field is being asked to manage. The founders who finish hardware companies in 2026 and 2027 will be the ones whose design history files were already written against that expectation, not the ones who heard the agency name it for the first time in May.

The Five Questions for a Regulated Hardware Company

The five-question framework in Founders Who Finish applies directly to the supplier-qualification design problem. Each question maps to a decision the founder has to settle before the bill of materials freezes.